» Authors » Lander Egana-Gorrono

Lander Egana-Gorrono

Explore the profile of Lander Egana-Gorrono including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 17
Citations 284
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Senatus L, Egana-Gorrono L, Lopez-Diez R, Bergaya S, Aranda J, Amengual J, et al.
Commun Biol . 2023 Mar; 6(1):280. PMID: 36932214
Atherosclerosis evolves through dysregulated lipid metabolism interwoven with exaggerated inflammation. Previous work implicating the receptor for advanced glycation end products (RAGE) in atherosclerosis prompted us to explore if Diaphanous 1...
2.
Manigrasso M, Rabbani P, Egana-Gorrono L, Quadri N, Frye L, Zhou B, et al.
Sci Transl Med . 2021 Nov; 13(621):eabf7084. PMID: 34818060
The macro- and microvascular complications of type 1 and 2 diabetes lead to increased disease severity and mortality. The receptor for advanced glycation end products (RAGE) can bind AGEs and...
3.
Almonte V, Uriyanghai U, Egana-Gorrono L, Parikh D, Oliveira-Paula G, Zhang J, et al.
Cardiovasc Res . 2021 Sep; 118(12):2718-2731. PMID: 34478521
Aims: Graft vascular disease (GVD), a clinically important and highly complex vascular occlusive disease, arises from the interplay of multiple cellular and molecular pathways. While occlusive intimal lesions are composed...
4.
Senatus L, MacLean M, Arivazhagan L, Egana-Gorrono L, Lopez-Diez R, Manigrasso M, et al.
Immunometabolism . 2021 Jun; 3(3). PMID: 34178389
Fundamental modulation of energy metabolism in immune cells is increasingly being recognized for the ability to impart important changes in cellular properties. In homeostasis, cells of the innate immune system,...
5.
Lopez-Diez R, Egana-Gorrono L, Senatus L, Shekhtman A, Ramasamy R, Schmidt A
Curr Cardiol Rep . 2021 Jun; 23(7):74. PMID: 34081211
Purpose Of Review: The cardiovascular complications of type 1 and 2 diabetes are major causes of morbidity and mortality. Extensive efforts have been made to maximize glycemic control; this strategy...
6.
Senatus L, Lopez-Diez R, Egana-Gorrono L, Liu J, Hu J, Daffu G, et al.
JCI Insight . 2020 Jul; 5(13). PMID: 32641587
Despite advances in lipid-lowering therapies, people with diabetes continue to experience more limited cardiovascular benefits. In diabetes, hyperglycemia sustains inflammation and preempts vascular repair. We tested the hypothesis that the...
7.
Egana-Gorrono L, Lopez-Diez R, Yepuri G, Ramirez L, Reverdatto S, Gugger P, et al.
Front Cardiovasc Med . 2020 Mar; 7:37. PMID: 32211423
Obesity and diabetes are leading causes of cardiovascular morbidity and mortality. Although extensive strides have been made in the treatments for non-diabetic atherosclerosis and its complications, for patients with diabetes,...
8.
Parikh D, Riascos-Bernal D, Egana-Gorrono L, Jayakumar S, Almonte V, Chinnasamy P, et al.
Sci Rep . 2020 Feb; 10(1):3594. PMID: 32107417
The allograft inflammatory factor (AIF) gene family consists of two identified paralogs - AIF1 and AIF1-like (AIF1L). The encoded proteins, AIF1 and AIF1L, are 80% similar in sequence and show...
9.
Egana-Gorrono L, Chinnasamy P, Casimiro I, Almonte V, Parikh D, Oliveira-Paula G, et al.
Atherosclerosis . 2019 Aug; 289:184-194. PMID: 31439353
Background And Aims: Allograft inflammatory factor-1 (AIF1) has been characterized as a pro-inflammatory molecule expressed primarily in the monocyte/macrophage (MP) lineage and positively associated with various forms of vascular disease,...
10.
Tort O, Escriba T, Egana-Gorrono L, de Lazzari E, Cofan M, Fernandez E, et al.
J Lipid Res . 2018 Sep; 59(11):2108-2115. PMID: 30213800
Cholesterol efflux (CE) capacity has been inversely associated with atherosclerosis and may provide an insight on inflammation occurring in human immunodeficiency virus (HIV) individuals. We address this by studying CE...